MIRA Pharmaceuticals, Inc. (MIRA)
| Market Cap | 27.65M +12.9% |
| Revenue (ttm) | n/a |
| Net Income | -31.04M |
| EPS | -0.86 |
| Shares Out | 42.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 128,635 |
| Open | 0.6351 |
| Previous Close | 0.6821 |
| Day's Range | 0.6260 - 0.6791 |
| 52-Week Range | 0.6000 - 2.4500 |
| Beta | 1.49 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About MIRA
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dem... [Read more]
Financial Performance
Financial StatementsNews
Mira advances Ketamir-2 to chemotherapy-induced peripheral neuropathy
Mira Pharmaceuticals (MIRA) announced that, following review and comments from the FDA, the Phase 2a protocol evaluating Ketamir-2 in chemotherapy-induced peripheral neuropathy has been submitted for ...
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics...
Mira Pharmaceuticals initiated with a Buy at Maxim
Maxim analyst Jason McCarthy initiated coverage of Mira Pharmaceuticals (MIRA) with a Buy rating and $3.50 price target
Mira Pharmaceuticals announces results from MIRA-55 studies
Mira Pharmaceuticals (MIRA) announced results from completed seven-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs. MIRA-55 is the company’s investigational ora...
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics...
Mira reports positive results in 7-day dog study for obesity candidate SKNY-1
Mira Pharmaceuticals (MIRA) announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrates dose-dependent systemic exposure and rapid absor...
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
Obesity Treatment Candidate Designed to Preserve Lean Body Mass Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Ph...
Mira Pharmaceuticals provides update on MIRA-55, SKNY-1
Mira Pharmaceuticals (MIRA) announced continued advancement of its two preclinical programs, MIRA-55, an investigational oral non-opioid drug candidate for chronic inflammatory pain, and SKNY-1, an in...
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics,...
Mira Pharmaceuticals reports formulation results for MIRA-55
MIRA Pharmaceuticals (MIRA) announced results from preclinical studies evaluating optimized oral formulations of MIRA-55, the Company’s oral drug candidate being developed as a non-opioid therapy for ...
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain and Liver Distribution Following Oral Administration MIAMI, FL / ACCESS Newswire / July 10, 2026 / MIR...
Mira Pharmaceuticals reports SKNY-1 formulation results
MIRA Pharmaceuticals (MIRA) announced results from preclinical studies evaluating the optimized oral formulation of SKNY-1, the Company’s oral drug candidate being developed for obesity and addiction-...
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with Once-Daily Dosing Potential MIAMI, FL / ACCESS Newswire / July 6, 2026 / MIRA Pharmace...
Mira Pharmaceuticals reports preclinical pharmacology data on Mira-55
MIRA Pharmaceuticals (MIRA) announced new preclinical pharmacology data on Mira-55, the Company’s cannabinoid analog in development for chronic inflammatory pain. Mira-55 is designed to act on the sam...
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
Data show Mira-55 does not produce the central nervous system effects associated with THC and acts through a distinct pharmacological mechanism, while demonstrating anxiolytic activity, which THC does...
Mira Pharmaceuticals submits Phase 2a trial protocol to U.S. FDA for Ketamir-2
Mira Pharmaceuticals (MIRA) announced the submission of a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration, FDA, for Ketamir-2, the Company’s proprietary oral NMDA receptor mo...
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
Randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and dose-response efficacy of oral Ketamir-2 at a leading U.S. cancer center MIAMI, FL / ACCESS Newswire / June 17,...
Mira Pharmaceuticals secures worldwide rights to MIRA-55, SKNY-1
MIRA Pharmaceuticals (MIRA) announced the execution of an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, securing worldwide exclusive rights to MIRA-55 and SKNY-1. The amended agr...
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
Agreement Establishes Global Exclusivity Across MIRA's Core Therapeutic Pipeline and Enhances Strategic Flexibility for Future Licensing and Partnership Opportunities MIAMI, FL / ACCESS Newswire / Jun...
Mira Pharmaceuticals secures worldwide rights for Ketamir-2
MIRA Pharmaceuticals (MIRA) announced the execution of Amendment No. 1 to its exclusive Ketamir-2 license agreement with MIRALOGX, expanding the Company’s licensed territory from the United States, Ca...
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
Expanded Global Intellectual Property Portfolio Enhances Strategic Flexibility and Long-Term Value Potential for Ketamir-2 MIAMI, FL / ACCESS Newswire / May 27, 2026 / MIRA Pharmaceuticals, Inc. (NASD...
Mira Pharmaceuticals management to meet with Maxim
Meeting to be held on May 27 hosted by Maxim.
Mira announces results from Phase 1 trial evaluating Ketamir-2
MIRA Pharmaceuticals (MIRA) announced positive unblinded results from its completed Phase 1 clinical trial evaluating Ketamir-2, the Company’s proprietary selective oral NMDA receptor modulator. The r...
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
Selective oral NMDA receptor modulator demonstrated favorable safety, tolerability, and pharmacokinetic profile supporting planned Phase 2a development in chemotherapy-induced peripheral neuropathy MI...
Mira announces acceptance of peer-reviewed SKNY-1 manuscript
Mira Pharmaceuticals (MIRA) announced the acceptance and publication of a peer-reviewed manuscript describing the preclinical pharmacology and activity of SKNY-1, the Company’s oral investigational dr...